REGENXBIO Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
REGENXBIO Inc. (RGNX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $38.52 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $38.52M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $17.26M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $36.50M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $60.83M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $38.52M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.26M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $36.50M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $60.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $81.59M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $132.13M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $59.56M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $58.65M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $59.80M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $115.00M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $36.55M 10-K · filed 2026-03-05 |
| 2023-09-30 | $55.30M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $70.86M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $72.12M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $98.98M 10-K · filed 2025-03-13 |
| 2022-09-30 | $120.57M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $123.40M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $193.90M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $347.24M 10-K · filed 2025-03-13 |
| 2021-09-30 | $229.72M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $258.40M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $292.81M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $339.76M 10-K · filed 2024-02-27 |
| 2020-09-30 | $94.55M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $95.55M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $70.74M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $70.84M 10-K · filed 2023-02-28 |
| 2019-09-30 | $80.65M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $56.20M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $56.91M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $76.61M 10-K · filed 2022-03-01 |
| 2018-09-30 | $142.65M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $107.11M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $72.09M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $46.88M 10-K · filed 2021-03-01 |
| 2017-09-30 | $60.11M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $57.87M 10-Q · filed 2018-08-08 |
| 2016-12-31 | $25.07M 10-K · filed 2020-02-26 |
| 2015-12-31 | $54.12M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |